Purpose: The primary objective of the current study was to investigate the characteristics of synchronous cancers in gastric cancer patients.
Materials And Methods: We analyzed the 2,237 patients who were diagnosed between December 2000 and December 2003 with gastric cancer and synchronous cancers of organs other than the stomach.
Results: 73 (3.3%) of a total of 2,237 gastric cancer patients had synchronous primary cancers. Among these 73 patients, 71 had one synchronous cancer, and two patients had double synchronous cancers. Colorectal cancer (26 patients, 34.7%) was the most frequently encountered synchronous cancer, followed by cancer of the lung (16 patients, 21.3%), esophagus (13 patients, 17.2%), and liver (8 patients, 10.7%). Synchronous cancers were detected with increased frequency in the elderly, in the patients with multiple gastric cancers, in the patients with differentiated gastric cancer, and in the patients with early gastric cancer, as determined on univariate analysis, but the differentiation of gastric cancers was the only risk factor for synchronous cancers on the multivariate analysis.
Conclusions: The differentiation of gastric cancer cells may be a risk factor for synchronous cancers in gastric cancer patients. Careful surveillance by the physician for synchronous cancer is warranted for the patients suffering from gastric cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741660 | PMC |
| http://dx.doi.org/10.4143/crt.2006.38.1.25 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
C118P Suppresses Gastric Cancer Growth via Promoting Autophagy-Lysosomal Degradation of RAB1A.
Pharmaceutics
December 2024
New Drug Screening and Pharmacodynamics Evaluation Center, National Key Laboratory for Multi-Target Natural Drugs, China Pharmaceutical University, Nanjing 210009, China.
: Gastric cancer (GC) is the leading cause of cancer-related deaths worldwide. C118P, a microtubule inhibitor with anti-angiogenic and vascular-disrupting activities, was proven to be cytotoxic to various cancer cell lines. This study aimed to explore the anti-tumor effect of C118P against gastric cancer and identify its potential target.
View Article and Find Full Text PDFVitamin B, B, and B Intakes and Risk of Gastric Cancer: Findings from a Case-Control Study.
Nutrients
December 2024
University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA 15261, USA.
Background/objectives: Gastric cancer is one of the leading malignancies worldwide. B vitamins play important roles in DNA synthesis and methylation because they are considered co-enzymes in one-carbon metabolism. There is inconclusive evidence regarding the associations between dietary vitamins B, B, and B with the risk of gastric cancer in different epidemiologic studies.
View Article and Find Full Text PDFPathological In Vivo Analysis of Helicobacter DNA Infection in Stomach Cells Using Carbon Nanotube Microsensor.
Microorganisms
December 2024
Biosensor Research Institute, Seoul National University of Science & Technology, Seoul 01811, Republic of Korea.
The WHO has classified Helicobacter pylori as a group 1 carcinogen for stomach cancer since early 1994. However, despite the high prevalence of Helicobacter pylori infection, only about 3% of infected people eventually develop gastric cancer.Biomolecular detections of Helicobacter pylori(HP) were compared using specially modified sensors and fluorine immobilized on a carbon nanotube (HFCNT) electrode, which yielded sensitive results.
View Article and Find Full Text PDFInhibition, Gastritis Attenuation, and Gut Microbiota Protection in C57BL/6 Mice by NCUH062003.
Microorganisms
December 2024
State Key Laboratory of Food Science and Resources, Nanchang University, No. 235 Nanjing East Road, Nanchang 330047, China.
(), one of the most prevalent pathogenic bacteria worldwide, is the leading cause of gastritis, gastric intestinal metaplasia, and gastric cancer. Antibiotics, the conventional treatment for eliminating , often lead to severe bacterial resistance, gut dysbiosis, and hepatic insufficiency and fail to address the inflammatory response or gastric mucosal damage caused by infection. In this study, based on 10-week animal experiments, two models of NCUH062003 for the prophylaxis and therapy of infection in C57BL/6 mice were established; a comprehensive comparative analysis was performed to investigate the anti- effect of probiotics, the reduction in inflammation, and repair of gastric mucosal damage.
View Article and Find Full Text PDFAttenuates 5-Fluorouracil-Induced Intestinal Mucositis in Mice.
Pharmaceuticals (Basel)
December 2024
Laboratory of Gastrointestinal Physio-Pharmacology (LEFFAG), Federal University of Ceará, Coronel Nunes de Melo Street, 1315 Rodolfo Teófilo, Fortaleza 60416-030, CE, Brazil.
5-Fluorouracil (5-FU) is an antimetabolite widely prescribed in cancer treatments, but its use in highly proliferative tissues can cause significant problems such as mucositis. is a probiotic commonly used for protection against acute diarrhea, gastrointestinal dysbiosis and inflammatory bowel diseases. We investigated the effect of on 5-FU intestinal mucositis in mice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!